title: Advanced Lung Cancer Is Associated with Decreased Expression of Perforin, CD95, CD38 by Circulating CD3+CD8+ T Lymphocytes.
abstract: It is known that dysregulation of the immune system is closely related to the development of lung cancer and that CD8+T lymphocytes play a critical role in antitumor immunity. We analyzed the percentage of CD3+CD8+ T cells in peripheral blood, and expressions of the activated molecules, perforin, CD95, CD28, HLA-DR and CD38 in circulating CD3+CD8+ T cells from 68 lung cancer cases with stage I∼II and 61 lung cancer cases with stage III∼IV by flow cytometry. 61 lung cancer cases with stage III∼IV were followed up for more than 6 months and survival time was recorded. The percentages of perforin+ cells, CD95+ cells and CD38+ cells in fresh CD3+CD8+ T lymphocytes of stage III∼IV group were lower than those of stage I∼II group (p=0.021; p=0.043; p=0.036). And an increased percentage of CD3+CD8+perforin+ cells was shown to have a positive effect on the survival time in stage III∼IV lung cancer patients (p=0.043). Advanced lung cancer patients have characteristics of impairment in the cytotoxicity of circulating CD3+CD8+ T lymphocytes and perforin expression in circulating CD3+CD8+ T cells might be used as a prognostic biomarker for the advanced lung cancer.
authors.affiliation: Cell and Molecular Biology Laboratory, Zhoushan Hospital, Zhejiang, P.R. China.
authors.forename: Liyun
authors.initials: L
authors.lastname: Xu
authors.affiliation: Cell and Molecular Biology Laboratory, Zhoushan Hospital, Zhejiang, P.R. China.
authors.forename: Dongdong
authors.initials: D
authors.lastname: Chen
authors.affiliation: Cell and Molecular Biology Laboratory, Zhoushan Hospital, Zhejiang, P.R. China.
authors.forename: ChangChang
authors.initials: C
authors.lastname: Lu
authors.affiliation: Cell and Molecular Biology Laboratory, Zhoushan Hospital, Zhejiang, P.R. China.
authors.forename: Xiaoguang
authors.initials: X
authors.lastname: Liu
authors.affiliation: Department of Oncology, Cancer Biotherapy Center, Zhejiang Province People's Hospital, Hangzhou, Zhejiang, P.R. China.
authors.forename: Guoqing
authors.initials: G
authors.lastname: Wu
authors.affiliation: Department of Cardio-Thoracic surgery, Zhoushan Hospital, Zhejiang, P.R. China zhoushanzhang1@126.com.
authors.forename: Yongkui
authors.initials: Y
authors.lastname: Zhang
mesh_terms: D051997:ADP-ribosyl Cyclase 1 / Q000097:blood / Q000378:metabolism; D000368:Aged; D015703:Antigens, CD / Q000097:blood* / Q000378:metabolism; D018106:CD28 Antigens / Q000097:blood / Q000378:metabolism; D017252:CD3 Complex / Q000378:metabolism; D018414:CD8-Positive T-Lymphocytes / Q000378:metabolism* / Q000473:pathology; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000276:immunology / Q000401:mortality / Q000473:pathology*; D008297:Male; D008562:Membrane Glycoproteins / Q000097:blood / Q000378:metabolism; D008875:Middle Aged; D054353:Perforin / Q000097:blood* / Q000276:immunology; D019014:fas Receptor / Q000097:blood / Q000378:metabolism
chemical_list: D015703:Antigens, CD; D018106:CD28 Antigens; D017252:CD3 Complex; C491901:FAS protein, human; D008562:Membrane Glycoproteins; D019014:fas Receptor; D054353:Perforin; C498154:CD38 protein, human; D051997:ADP-ribosyl Cyclase 1
keywords: Advanced lung cancer; CD3+CD8+T lymphocyte; CD95; perforin